Domainex announces the grant of US and European patents for its lead programme, targeting IKK epsilon and TBK1 for the Treatment of diseases such as COPD and Psoriasis


11th May 2015 Domainex Ltd. (Cambridge, UK) today announced that The US and European Patent Offices have now granted Domainex patents US 8,962,609 and EPA 11738026.1 for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1. Domainex is a biotech company developing a pipeline of cutting edge, first-in-class pre-clinical drugs based upon two …




Continue reading

Domainex prepares for expansion


Domainex prepares for expansion as it announces the appointment of Barry Knight as Chief Financial Officer and Company Secretary, and Thomas Mander as Chief Operating Officer Barry Knight is a Chartered Accountant and brings extensive financial expertise to Domainex, having been an executive director for Life Sciences companies for more than 25 years. Barry was …




Continue reading